Source link : https://www.newshealth.biz/health-news/more-support-for-tenecteplase-in-ischemic-stroke/
The bolus thrombolytic agent, tenecteplase, narrowly failed to show non-inferiority to alteplase in the TASTE clinical trial within 4.5 hours of symptom onset selected by perfusion imaging in patients with acute ischemic stroke. However, the trial was stopped early after previous studies had shown the non-inferiority of tenecteplase to alteplase, thus reducing its power. In […]
Author : News Health
Publish date : 2024-05-17 05:42:14
Copyright for syndicated content belongs to the linked Source.
in Health